Wall Street analysts expect that MedAvail Holdings, Inc (NASDAQ:MDVL) will report earnings per share (EPS) of ($0.30) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for MedAvail’s earnings. MedAvail reported earnings per share of ($1.08) in the same quarter last year, which suggests a positive year-over-year growth rate of 72.2%. The company is scheduled to announce its next earnings results after the market closes on Wednesday, May 12th.
According to Zacks, analysts expect that MedAvail will report full year earnings of ($1.16) per share for the current financial year. For the next financial year, analysts expect that the business will report earnings of ($0.81) per share. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover MedAvail.
MDVL has been the subject of several analyst reports. Cowen boosted their price target on shares of MedAvail from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday, April 12th. Zacks Investment Research cut shares of MedAvail from a “hold” rating to a “sell” rating in a report on Friday, April 9th.
NASDAQ MDVL traded down $0.48 on Tuesday, hitting $13.11. 11,602 shares of the stock were exchanged, compared to its average volume of 92,942. The company has a current ratio of 2.71, a quick ratio of 1.11 and a debt-to-equity ratio of 0.15. MedAvail has a fifty-two week low of $9.00 and a fifty-two week high of $46.20. The firm has a market cap of $418.80 million, a P/E ratio of -3.21 and a beta of 1.20. The firm has a 50-day simple moving average of $13.91.
A number of hedge funds have recently added to or reduced their stakes in the stock. Pura Vida Investments LLC purchased a new stake in MedAvail in the 4th quarter valued at $36,876,000. Monashee Investment Management LLC purchased a new stake in MedAvail in the 4th quarter valued at $3,470,000. Endurant Capital Management LP purchased a new stake in MedAvail in the 4th quarter valued at $955,000. Royce & Associates LP purchased a new stake in MedAvail in the 4th quarter valued at $792,000. Finally, ExodusPoint Capital Management LP purchased a new stake in MedAvail in the 4th quarter valued at $471,000. Hedge funds and other institutional investors own 40.24% of the company’s stock.
MedAvail Company Profile
MedAvail Holdings, Inc operates as a technology enabled pharmacy company that embeds automated pharmacy services directly into clinics and other points of care through its proprietary technology. The company provides turnkey services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations.
See Also: Accumulation/Distribution
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MedAvail Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedAvail and related companies with MarketBeat.com's FREE daily email newsletter.